论文部分内容阅读
目的研究P 糖蛋白 (P gp)及肺耐药相关蛋白 (LRP)在骨肉瘤 (OS)中的表达及与临床病理特点的关系。方法 38例OS及 10例正常骨组织的石蜡切片 ,以P gp单克隆抗体C2 19及LRP单克隆抗体LRP56用SABC法进行免疫组化染色 ,并对有关临床及病理指标综合分析。结果OS中P gp及LRP阳性表达率分别为 5 5 2 6 %和 42 11% ,而正常骨组织均为阴性表达 ,两组间比较差异有显著意义(P <0 0 5 )。此外 ,P gp在转移组及外科分期较高组中的表达率高于未转移组及外科分期较低的病例组 (P <0 0 5 ) ;LRP在 <12岁或 >30岁年龄组中明显高于 12～ 30岁病例组 (P <0 0 5 )。结论 (1)P gp与LRP均介导OS的多药耐药 (MDR)。 (2 )人OS对化疗不敏感、预后差与OS组织中存在P gp及LRP有关。 (3)P gp与LRP的表达不相关 ,分别以独立机制介导OS的MDR。 (4 )用免疫组化法检测OS的P gp和LRP ,可作为临床常规筛选检测 ,并为指导制定合理的治疗方案和预后评估提供依据。
Objective To investigate the expression of P glycoprotein (P gp) and lung resistance-related protein (LRP) in osteosarcoma (OS) and its relationship with clinicopathological features. Methods Paraffin sections of 38 cases of OS and 10 cases of normal bone tissue were immunohistochemically stained with monoclonal antibody P2p C2 19 and LRP56 monoclonal antibody LRP56 by SABC method. The clinical and pathological parameters were comprehensively analyzed. Results The positive expression rates of P gp and LRP in OS were 5522.6% and 42%, respectively. The normal bone tissues were negative. There was significant difference between the two groups (P < 0.05). In addition, the expression of P gp in the metastasis group and the surgical stage was higher than that in the non-metastasis group and the surgical stage (P <0 05); LRP was in the <12 or >30 age group. It was significantly higher than the 12-30 year old group (P < 0.05). Conclusion (1) Both Pgp and LRP mediate OS multidrug resistance (MDR). (2) Human OS is insensitive to chemotherapy, and the poor prognosis is related to the presence of Pgp and LRP in OS. (3) There was no correlation between P gp and LRP expression, and the MDR of OS was mediated by an independent mechanism. (4) Detecting Pgp and LRP in OS by immunohistochemical method can be used as a routine clinical screening test, and provide basis for guiding the development of reasonable treatment plan and prognosis evaluation.